Pyrazinamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pyrazinamide: From Tuberculosis to Infectious Otitis Media
One-Sentence Summary
Pyrazinamide is a first-line anti-tuberculosis agent, standard therapy for pulmonary and extrapulmonary tuberculosis as part of multi-drug regimens. The TxGNN model predicts it may be effective for Infectious Otitis Media, but this top-ranked prediction currently has 0 clinical trials and 0 publications supporting it directly — the score reflects graph proximity to the tuberculosis node only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Tuberculosis (pulmonary and extrapulmonary) — no formal license text available; drug is not currently marketed in the evaluated jurisdiction |
| Predicted New Indication | Infectious Otitis Media |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 (model prediction only, no supporting trials/literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank. Based on the mechanistic notes captured elsewhere in this evidence pack, pyrazinamide is a prodrug that is only active against Mycobacterium tuberculosis within the acidic environment of macrophage phagosomes, and it is used exclusively as part of standard multi-drug anti-tuberculosis regimens (typically with rifampicin and isoniazid). This mechanism is highly pathogen-specific and does not confer general antibacterial activity against the organisms that typically cause otitis media (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis).
The top-ranked prediction, “Infectious Otitis Media,” has no clinical trial or literature evidence attached to it. According to the model’s own rationale note, the mechanistic link is inferred purely from the graph’s proximity to the tuberculosis node, without independent validation — this is explicitly flagged as unconfirmed.
Notably, several adjacent, lower-ranked predictions in this same evidence pack (rank 2 “middle ear disease,” rank 4 “chronic otitis media,” rank 5 “suppurative otitis media”) are supported by case-report literature describing tuberculous otitis media (TOM) — a rare but recognized extrapulmonary manifestation of TB in which pyrazinamide is already used as part of standard anti-TB therapy (e.g., PMID 26785789 documents pyrazinamide 25 mg/kg alongside rifampicin and isoniazid for 9 months). This suggests the TxGNN model may be capturing a real but narrow signal — TB spreading to the middle ear — rather than a genuinely new mechanism for general infectious otitis media. The rank-1 prediction itself, however, remains unsupported and should not be conflated with this TB-specific subgroup.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No marketing authorizations currently on record (total_licenses = 0). Pyrazinamide’s status in the evaluated jurisdiction is recorded as Not Marketed.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all currently unavailable — flagged in this evidence pack as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Infectious Otitis Media) has zero clinical trial or literature support — it is a pure TxGNN graph-proximity score with no independent validation, and the model’s own rationale acknowledges this. Combined with a Blocking gap on TFDA-equivalent label safety data (DG001) and missing MOA confirmation (DG002), the candidate cannot proceed past initial screening.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain official label warnings/contraindications before any S1 safety evaluation
- Resolve DG002: confirm mechanism of action via DrugBank API query
- Clarify whether “Infectious Otitis Media” is intended to capture the narrower, evidence-supported entity of tuberculous otitis media (see rank 2/4/5 predictions) — if so, re-scope the candidate around that better-validated extrapulmonary TB manifestation rather than general infectious otitis media
- Independent literature search specific to pyrazinamide (not just TB-otitis case reports as a class) before any evidence-level upgrade
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.